Department of Cardiology, Mitsubishi Kyoto Hospital, 1 Gosho-cho, Nishikyo-ku, Kyoto, Japan.
Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine, 54 Kawahara-cho, Shogoin, Sakyo-ku, Kyoto, Japan.
Eur Heart J Qual Care Clin Outcomes. 2018 Jul 1;4(3):200-207. doi: 10.1093/ehjqcco/qcy014.
To evaluate the influence of a history of cancer on clinical outcomes in coronary artery disease (CAD) patients who underwent percutaneous coronary intervention (PCI).
In the Coronary REvascularization Demonstrating Outcome Study in Kyoto (CREDO-Kyoto) PCI/coronary artery bypass grafting (CABG) Registry Cohort-2, there were 12 180 CAD patients who received PCI with stents. There were 1109 patients with a history of cancer (cancer group) and 11 071 patients without cancer (non-cancer group). The cumulative 5-year incidences of cardiac death and heart failure (HF) hospitalization were significantly higher in the cancer group than in the non-cancer group (12.4% vs. 7.5%, P < 0.001 and 12.1% vs. 7.6%, P < 0.001, respectively). Even after adjusting for confounders, the excess risk of the cancer group relative to non-cancer group for cardiac death and HF hospitalization remained significant [hazard ratio (HR) 1.27, 95% confidence interval (95% CI) 1.05-1.53; P = 0.02, and HR 1.39, 95% CI 1.13-1.68; P = 0.002, respectively]. Also, the cancer group had a trend toward higher adjusted risk for definite or probable stent thrombosis as compared with the non-cancer group (HR 1.49, 95% CI 0.99-2.16; P = 0.055). The cancer group had significantly higher adjusted risk for all-cause death, non-cardiac death, major bleeding, and non-CABG surgery than the non-cancer group, while the risks for myocardial infarction and stroke were neutral between the two groups.
Patients with a history of cancer at the time of PCI had increased risk for cardiac events such as cardiac death and HF hospitalization as well as non-cardiac events such as non-cardiac death, major bleeding, and non-CABG surgery.
评估癌症病史对行经皮冠状动脉介入治疗(PCI)的冠心病(CAD)患者临床结局的影响。
在京都经皮冠状动脉血运重建显示结局研究(CREDO-Kyoto)PCI/冠状动脉旁路移植术(CABG)注册队列-2 中,有 12180 例 CAD 患者接受了支架置入的 PCI。其中 1109 例患者有癌症病史(癌症组),11071 例患者无癌症(非癌症组)。癌症组的 5 年累积心脏死亡和心力衰竭(HF)住院发生率明显高于非癌症组(12.4%比 7.5%,P<0.001 和 12.1%比 7.6%,P<0.001)。即使在调整了混杂因素后,癌症组相对于非癌症组心脏死亡和 HF 住院的风险仍然显著升高[风险比(HR)1.27,95%置信区间(95%CI)1.05-1.53;P=0.02,和 HR 1.39,95%CI 1.13-1.68;P=0.002]。此外,与非癌症组相比,癌症组有较高的支架内血栓形成明确或可能的调整后风险趋势(HR 1.49,95%CI 0.99-2.16;P=0.055)。与非癌症组相比,癌症组的全因死亡、非心源性死亡、主要出血和非 CABG 手术的调整后风险明显较高,而两组之间的心肌梗死和卒中等风险无显著差异。
PCI 时患有癌症的患者发生心脏事件(如心脏死亡和 HF 住院)和非心脏事件(如非心源性死亡、主要出血和非 CABG 手术)的风险增加。